Oculopharyngeal muscular dystrophy (OPMD) is a rare late onset genetic disease affecting most profoundly eyelid and pharyngeal muscles, leading respectively to ptosis and dysphagia, and proximal limb muscles at later stages. A short abnormal (GCG) triplet expansion in the polyAbinding protein nuclear 1 (PABPN1) gene leads to PABPN1-containing aggregates in the muscles of OPMD patients. It is commonly accepted that aggregates themselves, the aggregation process and/or the early oligomeric species of PABPN1 are toxic in OPMD. Decreasing PABPN1 aggregate load in animal models of OPMD ameliorates the muscle phenotype. In order to identify a potential therapeutic molecule that would prevent and reduce aggregates, we tested guanabenz acetate (GA), an FDA-approved antihypertensive drug, in OPMD cells as well as in the A17 OPMD mouse model. We demonstrate that treating mice with GA reduces the size and number of nuclear aggregates, improves muscle force, protects myofibres from the pathology-derived turnover and decreases fibrosis. GA is known to target various cell processes, including the unfolded protein response (UPR), which acts to attenuate endoplasmic reticulum (ER) stress.
Introduction (700 words/ 4500 characters)
Oculopharyngeal muscular dystrophy (OPMD) is a late onset rare autosomal dominant muscular dystrophy. It affects 1:100000 people in Europe but it is more common in population groups such as the Bukharan Jews (1/600) and in Quebec (1/1000) likely due to founder effects (1, 2) . OPMD is characterized by progressive eyelid drooping (ptosis), swallowing difficulties (dysphagia) and proximal limb weakness. It is caused by a mutation in the poly(A) binding protein nuclear 1 (PABPN1) gene that introduces an abnormal expansion of alanine-encoding (GCN)n trinucleotide repeat in the coding region of exon 1 with 11-18 repeats leading to a mutant protein with an expanded number of alanines (expPABPN1, with 11-18 alanines instead of the normal 10) in the N terminal domain (3) . PABPN1 is involved in several steps of mRNA and non-coding RNA biogenesis: PABPN1 controls mRNA poly(A) tail length (4, 5) and regulates the use of alternative polyadenylation (APA) sites (6, 7) with a direct effect on mRNA levels and stability.
It is involved in splicing regulation (8, 9) and in the long non-coding RNA (lncRNAs) (10) and small nucleolar RNA (snoRNA) processing (11) . It also has an important role in poly(A)-mediated RNA decay or export from the nucleus (4) as well as in RNA hyperadenylation (12) .
Finally PABPN1 has been shown to be required for paraspeckle formation as well as for RNA editing (13) .
PABPN1 expression level varies across mouse and human tissues, and is exceptionally low in skeletal muscle (14) . Mutated expPABPN1 is prone to form intranuclear aggregates but only in skeletal muscle (15, 16) . To date the exact consequence of the presence of these aggregates in muscle still remains poorly understood but recent studies have suggested that expPABPN1 aggregates that also sequesters wild-type PABPN1 in heterozygous patients could itself contribute to phenotypes associated with OPMD by a loss of function mechanism (13, 14, (17) (18) (19) .
This pathological function of PABPN1 aggregates is supported by the fact that higher frequency of aggregates is observed in severe homozygous patients (20) . In addition, reducing PABPN1 aggregation by supplementing drugs such as trehalose or other supposed chaperones has consistently demonstrated enhanced cell survival in cell models of OPMD (21) (22) (23) and improved muscle weakness in both mouse and Drosophila models (2, 24, 25) . Apoptosis and deregulation of the ubiquitin-proteasome system have also been proposed as potential downstream pathological events triggered by the aggregates (26, 27) .
There is currently no cure for OPMD and one of the only option for patients is the surgical cricopharyngeal myotomy to improve swallowing and surgical treatment of ptosis. Some innovative therapies are under development, including a phase I/IIa cell therapy trial involving autologous myoblast transplantation that has shown improvement in the swallowing capacity of OPMD patients with a cell dose effect (28) . Several studies have shown promising results in animal models of the disease, mainly in Drosophila and in the A17 mouse model, where expPABPN1 is overexpressed under control of human skeletal muscle actin promoter (HSA1). A gene therapy approach tested in A17 mice showed a strong recovery from the disease (18) . As mentioned above, anti-aggregation pharmacological strategies have shown positive results both in vitro and in vivo in the same A17 mouse model of OPMD (2, 21, 25, 27) and intravenous injection of trehalose is currently being used in a phase II clinical trial (29) . Guanabenz acetate (GA), an FDA-approved antihypertensive drug agonist of α 2-adrenergic receptors (30) , was recently identified to display anti-prion activity through the inhibition of the protein folding activity (PFAR) mediated by the domain V of the large ribosomal RNA, which is a component of the large subunit of the ribosome (31, 32) . GA was shown to be effective in the Drosophila model of OPMD when provided as oral treatment in the food, where it decreased muscle degeneration and reduced the size of aggregates (24) . Deletions of the ribosomal DNA locus (encoding rRNAs mediating PFAR) was also shown to reduce OPMD phenotypes and act synergistically with sub-effective doses of 6-aminophenanthridine, a PFAR inhibitor like GA (24) , suggesting a mechanism involving the PFAR (33, 34) . Furthermore, GA has been shown to play a beneficial role in models of neurological diseases (e.g. Amyotrophic lateral sclerosis) by acting on the unfolded protein response (UPR). It has been proposed that GA could decrease protein burden in the endoplasmic reticulum (ER) and so increase the efficiency of ER chaperones by prolonging protein translation attenuation during ER stress (35, 36 producing the active transcription factor XBP1s that in turn triggers the expression of several genes involved in protein folding. The third pathway is operated by the activating transcription factor 6 (ATF6), a receptor that under ER stress and its dissociation to Grp78 is translocated to the Golgi where it is cleaved to produce a fragment which then acts as a transcription factor to promote expression of XBP1 mRNA and other proteins involved in protein folding. It has been
proposed that GA binds to PPP1R15A, thus preventing its binding to PP1c (37, 38) and prolonging eIF2α phosphorylation with the effect of reducing the accumulation of misfolded proteins in the ER (37, 39) , but these data are controversial (40, 41 ).
Here we show that GA supplementation tested in the same dose range used for the marketed hypertensive GA-based drug Wytensin, significantly reduces the number of aggregates, decreases fibrotic collagen deposition and pathological muscle turnover and improves muscle strength in the A17 mouse model of OPMD. As expPABPN1 expression in skeletal muscles induces the expression of ER stress markers, we studied the mechanism underlying the beneficial effects of GA in muscle cells and found that both Ire1α-and PERK-dependent branches of the UPR are affected by GA administration. Altogether, these results identify GA as a positive molecule for OPMD in the mouse model; they also suggest that ER stress plays a role in OPMD and that the modulation of UPR in response to ER stress has therapeutic potential to attenuate PABPN1 aggregate toxicity.
Results

Guanabenz effectively reduces PABPN1 aggregates in OPMD muscle cells
GA has been shown to reduce the size of aggregates in a Drosophila model of OPMD (24) . We first tested GA in the OPMD Ala17 muscle cell model. When differentiated, this myogenic cellular model expresses PABPN1-Ala17, resulting in the formation of a large number of nuclear aggregates (42, 43) . GA was added to the cells at day 2 of differentiation and maintained in the medium for 72 additional hours. In these conditions, treatment with 10 µM of GA led to a significant reduction in the number and size of PABPN1-Ala17 aggregates (Fig 1A-C) , without altering cell differentiation (Figure S1A-D) . At lower GA concentrations (ranging from 0.1 to 1 µM), we observed a dose-dependent reduction in the size of PABPN1-Ala17 aggregates but no effect on their number ( Figure S2A-C) .
ER stress is detected in skeletal muscle of A17 mice
GA is known to affect the UPR in response to cellular ER stress (35) (36) (37) 44) . No data are available on the ER stress condition and the relative unfolded protein response in muscles of the A17 mouse model of OPMD. Upon ER stress, it has been shown that the lumen of the ER is enlarged (45, 46) . Using electron microscopy, we analyzed the skeletal muscle of A17 mice and observed that the muscle ER (sarcoplasmic reticulum, SR) was abnormally expanded in a number of glycolytic fibers suggesting that this cellular organelle is indeed under stress (Figure 2A ). In addition, analysis of gene expression profiles of A17 skeletal muscles compared to those of wildtype (WT) mice confirmed that the expression of ER genes (GO term: Endoplasmic reticulum subcompartment) is affected in OPMD mice ( Figure 2B ). This was further confirmed by qPCR analysis on A17 muscle cDNAs for several crucial UPR-related genes: the chaperones glucoseregulated proteins 78 and 94 (Grp78, Grp94), the DNA damage-inducible transcript 3 Ddit3 (also named Chop), the activating transcription factor 4 (Atf4; downstream of PERK branch) and the DnaJ homolog subfamily C member 3 (Dnajc3; downstream of ATF6 branch) ( Figure 2C ).
These data confirm that expPABPN1 expression in skeletal muscles induces the expression of ER stress markers, indicating that the A17 mouse is a relevant OPMD model to evaluate the effect of GA on ER stress and its therapeutic potential in vivo.
GA treatment induces a favorable change in stress response in Ala17 cells
GA is known to affect the UPR in response to cellular ER stress by prolonging the phosphorylation of the α subunit of eukaryotic translation initiation factor 2 on Ser 51 (P-eIF2α), a key component of the PERK branch of UPR, to slow down protein translation, decrease the ER protein accumulation in the ER and so leaving more time for the ER chaperones to correctly fold newly synthetized proteins (37) . While no effect was observed in GA-treated versus non-treated control cells, a strong increase in phosphorylated eIF2α (P-eIF2α) was observed in GA-treated Ala17 cells ( Figure 3A -B) compared to non-treated Ala17 cells. This effect was also observed at lower doses where phosphorylation was activated for all doses ranging from 10 to 0.05 μM of GA (data not shown). Significant changes in the expression of the same UPR-related genes were observed in Ala17 treated cells in which Grp78, Grp94, Ddit3, Atf4 and Dnajc3 RNA levels were upregulated compared to non-treated cells, while these levels were unchanged in control treated cells ( Figure 3C ). As Grp78 also activates the IRE1α branch of the UPR, we evaluated if Xbp1 splicing was affected by GA supplementation. A strong increase in the spliced form of Xbp1 (Xbp1s) was detected in GA-treated Ala17 cells ( Figure 3D ) while no effect was observed on This analysis showed that mice treated with GA were less active than mice injected with saline soon after GA administration (One-way ANOVA test, Figure S3A ). However, the same analysis performed in mice just before the last injection of the study (with mice that were not under the effect of the drug at the time of the analysis) indicated that animals chronically treated with GA for 13 weeks are as active as mice injected with saline (One-way ANOVA test Figure S3B) suggesting no detrimental effect of a prolonged treatment with GA in locomotor activity of these mice. Before harvesting the samples from the treated mice, the forelimb force was analyzed by grip strength analysis. A17 mice have weaker forelimbs strength than FvB WT mice (25, 49) .
The treatment with GA significantly increased the muscle strength of treated A17 mice compared to saline injected A17 mice ( Figure 4A ). To assess more precisely the muscle strength, TA muscles of saline and GA-treated mice were then analyzed by in situ electrophysiology force measurement. Muscles were stimulated with 9 consecutive trains of impulses from 10 to 180 Hz and the muscle strength provided after each train of stimulation was measured. GA treatment significantly increased the absolute maximal tetanic force generated by the muscles of A17 mice (25), cystamine (27) and trehalose in mice, with the latter progressed to clinical trial stages in OPMD patients (NCT02015481 on clinicaltrial.gov).
In this study, we tested the effect of GA in a cellular model of OPMD and its therapeutic potential in a relevant mouse model of the disease. First of all, we showed that GA decreases the percentage and size of nuclear aggregates both in vitro and in vivo. GA and 6AP have previously been shown to reduce the size of aggregates and improve the pathology in a Drosophila model of OPMD (24) . However, while 6AP was shown to use the ribosome-borne protein folding activity of the large ribosomal RNA (PFAR) mechanism to reduce the size of aggregates, the mechanism of action of GA has not been addressed. Several reports, in the context of other diseases, have shown that GA promotes the UPR to counteract ER stress (35, 36, 39) . It has been proposed that GA binds the regulatory subunit of protein phosphatase 1 (PPP1R15A), thereby preventing the dephosphorylation of eiF2α and then protein translation recovery following stress (37, 39) , although its exact mechanism of action remains controversial (41, 53) . Delaying protein translation recovery may thus allow the UPR downstream chaperones (e.g. GRP78, GRP94) to have more time to cope with the impaired ER homeostasis. Here we show that GA promotes UPR in models of OPMD by acting through the UPR pathway initiated by PERK. In response to GA supplementation, we observed both an increase in phosphorylation of eiF2α and an increase in Xbp1 splicing. It has been described that Xbp1 splicing is regulated by activation of both PERK (through increased expression of Atf4 that is known to enhance Xbp1 splicing (54) (65, 66) would make them less available for normal cellular functions, which could lead to ER stress.
Recently, it has been demonstrated that PABPN1 protein regulates nuclear structure and homeostasis of Ca 2+ (67) . The ER is an essential intracellular organelle for many cell functions including the maintenance of Ca 2+ homeostasis. Calcium is one of the key regulators of cell survival and can induce ER stress-mediated apoptosis (68, 69) mainly through mitochondrial cell death (70) . It has been shown that PABPN1 mutation in OPMD gives rise to multiple Ca 2+ defects such as alterations of the sarcoplasmic reticulum (SR) Ca 2+ content, inhibition of the voltage-gated SR calcium release and reduced expression of ryanodine receptor (67) . Moreover, the presence of TNNT3 pre-mRNA in nuclear aggregates (42) is associated with aberrant calcium sensitivity in muscle fibres. These studies show that disturbance of Ca 2+ homeostasis plays a role in OPMD physiopathology and suggests that this could be one of the major causes of ER stress in OPMD. Furthermore OPMD has been proposed as a premature-ageing disease (17) and ER stress is prone to be activated in aging since age-related changes such as increased oxidative stress, protein misfolding, impairment of calcium homeostasis and disturbance of protein synthesis are observed when the protein quality is altered (71) . Similarly, the enrichment analysis of transcriptomic data from the OPMD mouse revealed ER as one of the top-five deregulated cellular components.
Following the positive effect of GA described in the Drosophila model of OPMD, this study is the first demonstration of the effectiveness of GA in a mammalian model of OPMD. Here, we decided to dose the mice with 12 mg/kg/week as this translates, after conversion for the body surface area, to approximately 10 mg/day in a 70 kg human being which is in the mid-range for the administration of Wytensin, a recently discontinued anti-hypertensive drug whose active ingredient is GA (47). GA i.p. treatment efficiently reduced the percentage of nuclei containing aggregates while simultaneously decreasing muscle fibrosis and improving muscle strength.
Furthermore by providing the drug via oral feeding, we demonstrated that the drug was still active and able to decrease the percentage of aggregates using the oral route of delivery, which is compatible with clinical application in humans. A direct comparison with trehalose, the only antiaggregate therapeutic strategy that has yet progressed to clinical application for OPMD, is impossible due to the different doses, route of delivery and outcome measures used to study these compounds. However the efficacy on reducing the amount of aggregates and the functional muscle improvement seem to be at least comparable if not substantially better after administration of GA, and with the further advantage that GA is already a well-characterized drug that entered the market although for a different pathological condition. This drug (ie Wytensin) was discontinued mainly due to some side-effects (e.g. dizziness and lethargy) that we also observed in the current study soon after dosing the mice. However, our study demonstrates that the chronic administration with GA, at least at the doses used, does not affect the locomotor activity in the long term. In conclusion, we suggest that GA ameliorates OPMD acting, at least partially, by finely modulating the ER stress response and reducing the aggregate formation. GA and novel GA derivatives thus have significant therapeutic potential for translation into clinical trials for the treatment of OPMD.
Materials and methods
Drug preparation
For in vitro experiments, Guanabenz acetate (GA) (G-110, Sigma) was prepared in DMSO at a stock concentration of 100 mM. Fresh aliquots were used for each new experiment at concentration ranging from 0.1 to 20 μ M. For the intraperitoneus (IP) injection, GA was first prepared in 5% DMSO and then diluted to the final concentration at 4 mg/kg of bodyweight with saline (NaCl 0.9% in water). For the oral feeding experiments, food supplemented with GA was prepared using the 2016.12 based diet provided by Envigo.
Cell culture
Primary immortalized mouse myoblasts H2KB IM2 (control cells) are derived from conditionally immortalized mice using a temperature-sensitive SV40 large T-antigen (tsA58) transgene (72) .
Mutated PABPN1 (Ala17) and wild-type PABPN1 (Ala10) stable cell lines have been established from IM2 cells transfected with a plasmid containing either mutated or wild type PABPN1 under a desmin promoter driving myotube-specific expression (43) . Cells were cultivated on matrigel coated surface in DMEM supplemented with 20% of foetal calf serum (Invitrogen), 0.5% of chick embryo extract (Seralab), 100 U/ml penicillin-streptomycin antibiotic (Thermofisher) and 10 U/ml interferon-gamma (Millipore) at 33°C in a humidified 5% CO2 air atmosphere. For Ala10 and Ala17 cell lines containing a resistance gene, 500 µg/ml de geneticin (G418; Life Technologies) was added to the media. At 90% of confluency, cells were differentiated in DMEM supplemented with 10% horse serum and 1% penicillin-streptomycin at 37°C in a 5% CO 2 humidified atmosphere.
PABPN1 immunostaining in cells:
For immunostaining, H2KB cells were cultivated in Ibidi 35 mm Dishes (Biovalley). 
RT-PCR and Real-time qRT-PCR
Total RNA was extracted from cell and skeletal muscle samples using Trizol reagent (Invitrogen) according to the manufacturer's instructions. RNA quality and purity was determined using a ND-1000 NanoDrop spectrophotometer (NanoDrop Technologies). RNA (100 ng for human muscle biopsies, 1 µg for cell pellets and mouse muscle biopsies) was reverse transcribed using Table S1 .
Mice
A17 transgenic mice have been previously described (25, 49) . Male A17 and wild-type FvB (WT) controls were generated by crossing the heterozygous carrier strain A17 with FvB mice. 
Drug administration
For the systemic treatment of OPMD a total of 12 mg/kg/week of GA was administered using 
Assessment of functional readouts in living mice
Mouse open-field behavioural activity Soon after the first i.p. injection of GA or saline, activity of mice was evaluated for 60 minutes (12 bins of 5 minutes each) using open field behavioral monitoring and data obtained per each mouse were averaged. Activity cages from Linton Instruments were used and data were collected using Amonlite software (vs 1.4). During the last 2 weeks of treatment with either oral feeding or intraperitoneal injections, the same cages were used to monitor the activity of treated mice according to a protocol designed following the TREAT-NMD guidelines (TREAT-NMD SOP:
DMD_M.2.1.002). Briefly, mice were acclimatized to the test chamber for 60 min every day for 4 consecutive days. On the days of data collection, mice were acclimatized for 30 min before data acquisition and data were then acquired every 5 minutes for 1h. This protocol was repeated for 4 days and data obtained per each mouse were averaged. As described in Results, only the first 30 minutes of analyses were considered indicative of the locomotor behavior.
Grip strength test
The forelimb strength of mice treated with either oral feeding or i.p. injections was assessed using a commercial grip strength monitor (Linton Instrumentation, Norfolk, UK). The protocol described in the TREAT-NMD guidelines was used for the oral feeding experiment (5 tests per mouse over a 3-day period, TREAT-NMD SOP: DMD_M.2.2.001). Mice, held from the tail, were allowed to grab a metal mesh attached to a force transducer and the force produced after a gentle pull, was recorded. 30 seconds were left between each of 5 sequential tests per mouse per day. Data were expressed as gram force per gram of the initial body weight. While behavior of the mice orally fed with drugs was normal and similar along the 3-days long procedure, we observed that all mice treated with chronic i.p. injections (and then manipulated thrice/week by the operator) voluntarily did not grab the mesh and preferred to be dragged during both the second and the third days of analyses, so only the measurements obtained from the 1 st day of analysis were used for the study.
In situ muscle physiology
TA muscle strength was measured by in situ muscle physiology performed under terminal anesthesia using a protocol already reported in (74) . Briefly 24h after the last injection of saline or GA, muscle function was assessed using tibialis anterior muscles of each mouse. Mice were deeply anesthetized and were carefully monitored throughout the experiment. The distal tendon of the TA muscle was dissected and tied with 4.0 braided surgical silk (Interfocus, Cambridge, UK). The sciatic nerve was exposed and superfluous branches axotomized. The TA tendon was fixed to the lever arm of a 305B dual-mode servomotor transducer (Aurora Scientific, Aurora, Ontario, Canada) via a custom made steel s-hook. Bipolar platinum electrodes located in the distal part of common peroneal nerve, were used to stimulate using supramaximal square-wave 
Samples harvesting, processing and storing
Animals were all culled at the end of the study and after the functional analyses. Tibialis anterior (TA), extensor digitorum longus (EDL), soleus (SOL) and gastrocnemius (GAST) muscles were harvested from mice treated with i.p injections and TA, EDL and SOL muscles were collected from mice treated with oral feeding. Muscles from a leg were snap-frozen in liquid nitrogen for WB and RNA studies and the muscles of the contralateral leg were mounted in corks using OCT and frozen in pre-chilled isopentane in liquid nitrogen for histological analyses. All samples were stored at -80°C before analysis. 
Immunostaining and histological analyses
Image acquisition and analysis
Images were visualized using an Olympus BX60 microscope (Olympus Optical, Hamburg, Germany), digitalized using a CCD camera (Photometrics CoolSNAP fx; Roper Scientific) and analyzed using MetaView image analysis system (Universal Imaging, Downington, PA),
MetaMorph imaging system (Roper Scientific, Tucson, AZ, USA) software, and ImageJ 1.44o
(http://imagej.nih.gov/ij) for quantification analysis.
Electron microscopy
TA muscles were dissected, cut into small pieces and immediately fixed in 2% glutaraldehyde, 2% paraformaldehyde, 0.1M phosphate buffer. After abundant washes and 2% OsO 4 postfixation samples were dehydrated at 4°C in graded acetone including a 1% uranyl acetate in 70° acetone step and were finally embedded in Epon resin. Thin (70nm) sections were stained with uranyl acetate and lead citrate, observed using a Philips CM120 electron microscope (Philips Electronics NV) and photographed with a digital SIS Morada camera.
Gene profile analysis
Enrichment analysis have been performed on the 1099 differentially expressed genes (DEGs) from quadriceps muscles of 26-weeks old A17 mice previously deposited on GEO (GSE26604) (49) . The analysis have been done using overexpressed test (75) of clusterProfiler package (76) and genome wide annotation for Mouse (77) in R. The Benjamini & Hochberg correction method has been applied and results with a False Discovery Rate (FDR) lower than 5% and an absolute logFC higher than 0.6 have been kept.
Statistical Analysis
All data are mean values ± standard error of the mean. Statistical analyses were performed using the Student t-test and the one-way ANOVA with the Bonferroni post-hoc analysis as indicated.
GraphPad Prism (version 4.0b; GraphPad Software, San Diego California, USA) was used for the analyses. A difference was considered to be significant at *P < 0.05, **P< 0.01 or ***P < 0.001. Forelimb force of A17 mice treated with GA showed a trend towards an increase in strength compared to the force of mice treated with saline. Unpaired t-test, *p<0.05. ns, not significant.
Figures Legend
Data are presented as mean ± s.e.m. n=6-8 per group.
